Assistant Professor, Molecular Genetic Pathology and Neuropathology, Co-Director, Molecular Diagnostics Laboratory, University of Texas Health Science Center at Houston
BIOGRAPHY
APR 29, 2021 1:35 PM PDT
Experience with the Oncomine Precision Assay on Genexus System
Presented at:
OncomineWorld 2022: A Virtual NGS Education Meeting
Speaker
Abstract
In examining the potential adoption of the Oncomine Precision Assay, University of Texas Health had several criteria to consider, including the need for highly accurate detection of small samples quickly, despite having a small lab staff (three people). This session will examine the variety of mutations which the OPA Assay detects, and how the adoption of the Ion Torrent Genexus System allowed UT Health to minimize bench time and reduce turnaround time to as little as 2 days. Mutations reviewed will include NTRK, MET, ERBB2(HER2), ERBB3 EGFR, ESR1, RET, EML4-ALK, FGFR1, KRAS, BRAF, and more.
Learning Objectives:
1. Be able to describe the benefits of the Oncomine Precision Assay(OPA) for oncology on the Ion Torrent Genexus System
2. Be able to evaluate the various mutations detected by OPA assay in the testing of human research samples
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
Loading Comments...